Bettina Hamelin, PharmD, EMBA is the President and CEO of Ontario Genomics, an Ontario-based not-for profit organization dedicated to catalyzing and supporting the development and commercialization of genomics- and engineering biology-based solutions across key sectors of the economy to drive economic growth, improved quality of life and global leadership for Ontario.

Dr. Hamelin has over 30 years of experience in academia, industry, and not-for profit organizations. She has held positions of increasing responsibility in the biotech and pharma industries including leadership positions at BioChem Pharma (Associate Director, DMPK) and Pfizer (Head, Strategic Research Partnerships, Western Canada; Director Vaccines, Pfizer Canada; Medical Director, Pfizer Germany; Global Scout, Pfizer Inc.). Dr. Hamelin also has 10 years of academic research expertise as a tenured professor at Université Laval. Prior to her current role, she served as VP of NSERC’s Research Partnerships Directorate, where she was responsible for stimulating increased public/private sector collaboration and technology transfer by connecting the Canadian research enterprise to Canadian and global innovation partners.

Dr. Hamelin volunteers in the broader research and innovation community and serves on several advisory committees and the Boards of Directors of IRICoR and the Centre for Probe Development and Commercialization (CPDC) , and as a Mentor for the Creative Destruction Lab (CDL). Dr. Hamelin also chairs the National Engineering Biology Steering Committee and serves on Ontario’s COVID-19 Genomics Network Steering Committee.